glp-1 options for type 2 diabetes and obesity 2025 New Guidelines in Orforglipron, approved as Foundayo on

The S-LiTE trial provides the most direct clinical evidence supporting the role of exercise in lean mass retention during GLP-1 therapy

However, the natural GLP-1 has a very short half-life, lasting only 1-2 minutes in the bloodstream

465 Impaired GLP-1 secretion or reduced GLP-1R expression may result in aberrantly heightened sympathetic excitation

9.1 Criteria suggesting failed pharmacology rather than failed biology Several characteristics consistently indicate that a peptide system may have been abandoned prematurely due to pharmacologic or methodological limitations rather than biological inadequacy

These results demonstrate superior performance compared to other GLP-1 agonists, insulin, and placebo [23, 24, 25, 26]

Protecting that investment with appropriate treatment duration planning makes the extended course worthwhile for most patients